[Use of calcium antagonists in the therapy of coronary heart disease].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000139:chemically induced; D002118:Calcium / Q000037:antagonists & inhibitors*; D003327:Coronary Disease / Q000188:drug therapy*; D004110:Diltiazem / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use; D009566:Nitrates / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D013268:Stimulation, Chemical; D013610:Tachycardia / Q000139:chemically induced; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D009566:Nitrates; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D002118:Calcium
Der Einsatz von Calciumantagonisten in der Therapie der koronaren Herzkrankheit.